ALG-097558, Publications Safety and pharmacokinetics of single and multiple ascending doses of ALG-097558, a pan-coronavirus protease inhibitor, in healthy volunteers
ALG-097558, Publications Preclinical Antiviral Profile of ALG-097558, a Novel Pan-Coronavirus 3CL Protease Inhibitor
ALG-097558, Publications Preclinical Evaluation of ALG-097558:A Novel, Orally Bioavailable Pan-Coronavirus 3CLpro Inhibitor for the Treatment of COVID-19
ALG-097558 Dual Inhibition of SARS-CoV-2 and Human Rhinovirus with Protease Inhibitors in Clinical Development
ALG-097558, Publications Mutations L50F, E166A and L167F in SARS-CoV-2 3CLpro are Selected by a Protease Inhibitor In Vitro and are Associated with Resistance
ALG-097558, Publications Discovery of ALG-097558, a Novel 3CL Protease Inhibitor with Activity in the SARS-CoV-2 Hamster Infection Model
ALG-097558, Publications Discovery and Antiviral Activity of the Novel 3CL Protease Inhibitor ALG-097558 in the SARS-CoV-2 Hamster Infection Model